AngioDynamics, Inc. (ANGO)

NASDAQ: ANGO · Real-Time Price · USD
11.12
+0.07 (0.63%)
At close: Oct 8, 2025, 4:00 PM EDT
11.45
+0.33 (2.97%)
After-hours: Oct 8, 2025, 5:11 PM EDT
0.63%
Market Cap458.14M
Revenue (ttm)300.72M
Net Income (ttm)-32.10M
Shares Out 41.20M
EPS (ttm)-0.78
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume324,742
Open11.13
Previous Close11.05
Day's Range10.93 - 11.16
52-Week Range5.84 - 13.50
Beta0.78
AnalystsStrong Buy
Price Target19.33 (+73.83%)
Earnings DateOct 2, 2025

About ANGO

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company’s thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device tha... [Read more]

Sector Healthcare
IPO Date May 27, 2004
Employees 675
Stock Exchange NASDAQ
Ticker Symbol ANGO
Full Company Profile

Financial Performance

In 2025, AngioDynamics's revenue was $292.50 million, a decrease of -3.76% compared to the previous year's $303.91 million. Losses were -$33.99 million, -81.56% less than in 2024.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for ANGO stock is "Strong Buy." The 12-month stock price target is $19.33, which is an increase of 73.83% from the latest price.

Price Target
$19.33
(73.83% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

AngioDynamics: Discounted Sales Multiple With Real Growth Engines

AngioDynamics, Inc. remains a Buy, trading at a steep discount to peers despite double-digit MedTech growth and improving margins. ANGO's Med Tech division now drives 47% of sales, with strong perform...

6 days ago - Seeking Alpha

AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript

AngioDynamics, Inc. (NASDAQ:ANGO) Q1 2026 Earnings Call October 2, 2025 8:00 AM EDT Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO Conference C...

6 days ago - Seeking Alpha

Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points.

6 days ago - Benzinga

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

6 days ago - Business Wire

Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings

AngioDynamics, Inc. (NASDAQ:ANGO) will release earnings results for the first quarter, before the opening bell on Thursday, Oct. 2.

7 days ago - Benzinga

AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

20 days ago - Business Wire

AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul

AngioDynamics has completed a strategic transformation, divesting non-core assets and focusing on high-growth MedTech platforms, driving accelerating revenue and margin improvement. Recent results con...

7 weeks ago - Seeking Alpha

AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

2 months ago - Business Wire

AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...

2 months ago - Business Wire

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

2 months ago - Business Wire

AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript

AngioDynamics, Inc. (NASDAQ:ANGO) Q4 2025 Earnings Conference Call July 15, 2025 8:00 AM ET Company Participants James C. Clemmer - CEO, President & Director Stephen A.

3 months ago - Seeking Alpha

AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

AngioDynamics Inc. (NASDAQ: ANGO) on Tuesday posted a fourth-quarter 2025 adjusted loss of 3 cents per share, compared to the consensus for a per-share loss of 12 cents.

3 months ago - Benzinga

AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

3 months ago - Business Wire

AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

3 months ago - Business Wire

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

3 months ago - Business Wire

Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance

AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported a third-quarter 2025 adjusted EPS of 3 cents, compared to the consensus for a per-share loss of 13 cents.

6 months ago - Benzinga

AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript

AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2025 Earnings Conference Call April 2, 2025 8:00 AM ET Company Participants Jim Clemmer - President & CEO Stephen Trowbridge - EVP & CFO Conference Call Participa...

6 months ago - Seeking Alpha

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

6 months ago - Business Wire

AngioDynamics to Host Virtual Cardiovascular Investor Event

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

6 months ago - Business Wire

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

7 months ago - Business Wire

AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

7 months ago - Business Wire

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

8 months ago - Business Wire

AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares

AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins, boosting confidence in achieving high single-digit revenue growth and double-d...

9 months ago - Seeking Alpha

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...

9 months ago - Business Wire

AngioDynamics: A Surgical Approach To Market Growth

AngioDynamics, Inc.'s Q2 2025 earnings beat expectations, with non-GAAP EPS at -$0.04 and revenue at $73.02 million, driving a 35% stock surge. Med Tech division shines, with 25% revenue growth and ke...

9 months ago - Seeking Alpha